BPMC vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.
Blueprint Medicines vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Teva Pharmaceutical Industries presently has a consensus target price of $23.43, indicating a potential upside of 44.82%. Blueprint Medicines has a consensus target price of $124.95, indicating a potential upside of 31.15%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Blueprint Medicines.
Teva Pharmaceutical Industries received 784 more outperform votes than Blueprint Medicines when rated by MarketBeat users. However, 68.11% of users gave Blueprint Medicines an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
Teva Pharmaceutical Industries has a net margin of -9.91% compared to Blueprint Medicines' net margin of -13.19%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Blueprint Medicines' return on equity.
In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Blueprint Medicines. MarketBeat recorded 27 mentions for Teva Pharmaceutical Industries and 20 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.87 beat Teva Pharmaceutical Industries' score of 0.70 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Blueprint Medicines has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Blueprint Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Teva Pharmaceutical Industries has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Summary
Teva Pharmaceutical Industries beats Blueprint Medicines on 11 of the 19 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:BPMC) was last updated on 3/25/2025 by MarketBeat.com Staff
